<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042609</url>
  </required_header>
  <id_info>
    <org_study_id>TRS4Vision</org_study_id>
    <nct_id>NCT05042609</nct_id>
  </id_info>
  <brief_title>A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma</brief_title>
  <official_title>A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsier Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsier Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops&#xD;
      compared to active comparator in subjects with active non-infectious anterior uveitis with or&#xD;
      without uveitic glaucoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Chamber Cell (ACC) grade on Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>In the US, the proportion of subjects with Anterior Chamber Cell (ACC) Grade=0 (0 cells) on Day 28 in the study eye.&#xD;
In Europe, the proportion of subjects with ACC Grade = 0 or 1 on Day 28 in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior Chamber Cell (ACC) grade on Day 21</measure>
    <time_frame>21 days</time_frame>
    <description>In the US: Proportion of subjects with ACC Grade=0 on Day 21 in the study eye. In the EU: Proportions of subjects with ACC Grade = 0 or 1 on Day 21 in the study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Day 1) in ACC Grade on Day 28 in the study eye</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Day 1) in ACC Grade on Day 21 in the study eye</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Non-infectious Anterior Uveitis</condition>
  <condition>Uveitic Glaucoma</condition>
  <arm_group>
    <arm_group_label>TRS01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRS01</intervention_name>
    <description>TRS01 eye drops Dosed four times a day (QID)</description>
    <arm_group_label>TRS01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved steroid eye drop</intervention_name>
    <description>FDA approved steroid eye drop Dosed four times a day (QID)</description>
    <arm_group_label>Active comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with active non-infectious anterior uveitis with anterior chamber cell Grade&#xD;
             2 (6-15 cells) or Grade 3 (16-30 cells) in the study eye that are without any&#xD;
             treatment or with Stable Medical Therapy requiring further treatment.&#xD;
&#xD;
          -  Have Best Corrected Visual Acuity (BCVA) vision â‰¥ 65 letters in the non-study eye&#xD;
             using Early Treatment Diabetic Retinopathy Study (ETDRS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding females or females.&#xD;
&#xD;
          -  History of or active significant ocular disease in either eye.&#xD;
&#xD;
          -  Uncontrolled intraocular pressure (IOP; defined as &gt;27mmHg) or narrow angle glaucoma&#xD;
             in either eye and/or are at risk of angle closure with dilating.&#xD;
&#xD;
          -  Poor posterior view due to limitation of dilation or media opacity that limits ability&#xD;
             to examine the posterior segment.&#xD;
&#xD;
          -  Cancer or melanoma that is actively treated with immunotherapy.&#xD;
&#xD;
          -  Certain clinically significant systemic diseases or conditions.&#xD;
&#xD;
          -  Receiving specific medication/interventions as specified per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lexitas Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Lexitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lexitas Clinical Trials</last_name>
    <phone>919-205-0012</phone>
    <email>clinicaltrials@lexitas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winter Haven</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marietta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waltham</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palisades Park</name>
      <address>
        <city>Palisades Park</city>
        <state>New Jersey</state>
        <zip>07650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexitas Clinical Trials</last_name>
      <phone>919-205-0012</phone>
      <email>clinicaltrials@lexitas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

